Ignite Creation Date:
2024-05-05 @ 11:48 AM
Last Modification Date:
2024-10-26 @ 9:13 AM
Study NCT ID:
NCT00136747
Status:
COMPLETED
Last Update Posted:
2018-05-21
First Post:
2005-08-25
Brief Title:
The Effects of Memantine and Bupropion on Acute Reinforcing and Conditioned Effects of Cigarettes - 1
Sponsor:
New York State Psychiatric Institute
Organization:
New York State Psychiatric Institute
Study Overview
Official Title:
Developing Medication For Tobacco Addiction NMDA Agents
Status:
COMPLETED
Status Verified Date:
2018-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
One of nicotines effects on the body is at the level of the NMDA receptors in the brain Memantine is a drug that also affects NMDA receptors making it a candidate for the treatment of nicotine addiction The purpose of this study is to evaluate the effectiveness of memantine using a laboratory model of tobacco addiction The investigators will compare the effects of memantine with bupropion medication currently used to facilitate smoking cessation
Detailed Description:
Tobacco use is the leading preventable cause of death in the United States Recent research on the effects of nicotine on the brain and behavior presents an opportunity to advance medication development Neurotransmission at NMDA receptors in the brain is associated with learning and memory and has been linked to many of nicotines effects on humans It is possible that altering NMDA neurotransmission may be helpful in treating nicotine addiction
The goal of this study is to develop a laboratory model for early-stage testing of new and existing compounds for the treatment of tobacco and nicotine addiction Specifically the study will assess the effect of memantine a non-competitive NMDA antagonist versus bupropion a medication currently used to facilitate smoking cessation on various behavioral aspects related to smoking behavior including reinforcement and cue-reactivity
This double-blind randomized assignment study will consist of three distinct phases placebo bupropion and memantine Each phase will include 10 days of outpatient medication maintenance followed by 3 days of inpatient testing During the outpatient phase study visits will occur every 2 to 3 days At these visits compliance and side effects of medication will be monitored smoking diaries will be collected and medication will be dispensed During the inpatient period participants will be allowed to smoke only at designated times A variety of assessment will be conducted including abstinence symptoms acute effects of cigarettes responses to cigarette cues and cigarette self-administration
The goal of this study is to develop a laboratory model for early-stage testing of new and existing compounds for the treatment of tobacco and nicotine addiction Specifically the study will assess the effect of memantine a non-competitive NMDA antagonist versus bupropion a medication currently used to facilitate smoking cessation on various behavioral aspects related to smoking behavior including reinforcement and cue-reactivity
This double-blind randomized assignment study will consist of three distinct phases placebo bupropion and memantine Each phase will include 10 days of outpatient medication maintenance followed by 3 days of inpatient testing During the outpatient phase study visits will occur every 2 to 3 days At these visits compliance and side effects of medication will be monitored smoking diaries will be collected and medication will be dispensed During the inpatient period participants will be allowed to smoke only at designated times A variety of assessment will be conducted including abstinence symptoms acute effects of cigarettes responses to cigarette cues and cigarette self-administration
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| R01DA017572 | NIH | None | None |
| R01DA017572-01 | NIH | None | None |
| DPMC | OTHER | NIDA | httpsreporternihgovquickSearchR01DA017572-01 |